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Abstract Over the last 15 years it has become clear that rare
but highly recognizable diseases of the central nervous system
(CNS), including newly identified forms of limbic encephali-
tis and other encephalopathies, are likely to be mediated by
antibodies (Abs) to CNS proteins. The Abs are directed
against membrane receptors and ion channel-associated pro-
teins that are expressed on the surface of neurons in the CNS,
such as N-methyl D-aspartate receptors and leucine-rich, gli-
oma inactivated 1 protein and contactin-associated protein like
2, that are associated with voltage-gated potassium channels.
The diseases are not invariably cancer-related and are there-
fore different from the classical paraneoplastic neurological
diseases that are associated with, but not caused by, Abs to
intracellular proteins. Most importantly, the new antibody-
associated diseases almost invariably respond to immunother-
apies with considerable and sometimes complete recovery,
and there is convincing evidence of their pathogenicity in
the relatively limited studies performed so far. Treatments in-
clude first-line steroids, intravenous immunoglobulins, and
plasma exchange, and second-line rituximab and cyclophos-
phamide, followed in many cases by steroid-sparing agents in
the long-term. This review focuses mainly on N-methyl D-
aspartate receptor- and voltage-gated potassium channel
complex-related Abs in adults, the clinical phenotypes, and
treatment responses. Pediatric cases are referred to but not
reviewed in detail. As there have been very few prospective
studies, the conclusions regarding immunotherapies are based
on retrospective studies.
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Introduction
Antibody (Ab)-mediated diseases of the central nervous sys-
tem (CNS) are one of the exciting aspects of clinical neurolo-
gy. The diseases are associated, and probably caused by, anti-
bodies (Abs) that bind to the surface of neurons. The condi-
tions can be very disabling and patients may need long-term
hospitalization, including intensive care, but eventually fol-
lowing immunotherapies, they make a substantial improve-
ment (see [1, 2]).
The distribution of the plasma cells that secrete the Abs and
the distribution of IgG throughout the parenchyma of the
brain, as well as the roles of other immune effector mecha-
nisms, are largely unexplored, but the Abs are thought to
either penetrate a leaky blood–brain barrier (BBB) or to be
synthesized mainly within the intrathecal compartment
(Fig. 1). This may differ between different Abs.
One of the key features of these new conditions with cell
surface Abs is that they are diagnosed by use of cell-based
assays. These assays use cells that have been engineered to
express on their surface one of the potential antigens (Ags).
The binding of the patient’s serum or cerebrospinal fluid
(CSF) IgG is detected with a fluorescent secondary antihuman
IgG, and the cells observed under fluorescence microscopy
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(Fig. 2). Some laboratories use live cells so that only Abs
binding to extracellular domains are detected, while others
find that fixed and permeabilized cells are equally suitable.
Ab assay kits for the majority of the Agtargets discussed here
are nowwidely available but require fixation for transport, and
the sensitivities are not widely established.
Here the Ab-mediated different diseases are described, with
an emphasis on what is known about treatment and outcomes.
N-Methyl D-aspartate Receptor
N-Methyl D-aspartate receptor (NMDAR) Ab encephalitis is
the most common Ab-mediated autoimmune encephalopathy
[3], accounting for 4 % of encephalitis of all causes, according
to a recent prospective study in England. It was first described
in 2005 [4] as a paraneoplastic syndrome associated with
ovarian teratomas in young women, and the antigenic target
was determined in 2007 [5]. The initial presentation of
NMDAR Ab encephalitis appears to evolve from a frequent,
but not invariable, prodromal stage, to a clinical presentation
with behavioral and personality changes and psychiatric fea-
tures, including psychosis, cognitive dysfunction, and
seizures, often occurring within the first few days of symptom
onset. These are followed days to weeks later by subcortical
features, such as movement disorder/dyskinesia, autonomic
dysfunction, central hypoventilation, and reduced conscious-
ness [6]. Finally the patients recover, often showing previous
features in reverse order. CSF and electroencephalography are
abnormal in the majority of patients [7, 8], and the findings
mirror the clinical course: CSF lymphocytosis and epilepti-
form changes are a common finding in the first 20 days of
the disorder, whereas CSF-specific oligoclonal bands and gen-
eralized slowing on electroencephalography tend to appear
later [6]. Magnetic resonance imaging findings are abnormal
in less than half of patients [7, 8], and when present are usually
nonspecific with transient fluid-attenuated inversion recovery
or T2 high signal of small cortical areas, basal ganglia,
brainstem, cerebellum, or white matter tracts, with some pre-
dominance of medial temporal lobe and hippocampal abnor-
malities [6, 7]. The clinical course is very often severe
with most patients requiring admission to intensive care
units and disability severity at the peak of disease,
reaching a score of 5 on the modified Rankin Scale
(mRS) in many [8]. Recovery is often protracted with
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Fig. 1 Potential pathogenic mechanisms in antibody (Ab)-mediated
autoimmune encephalopathy. The pathogenesis of Ab-mediated
encephalopathies is still unclear. Several potential triggers have been
proposed as the first determinant of an aberrant activation of the
immune system (1). In N-methyl-D-aspartate encephalitis it is well
recognized that a tumor (mainly an ovarian teratoma) or a herpetic
infection can precede the onset of the disease, but in the majority of
cases the trigger remains unknown. In the peripheral circulation B
lymphocytes, after interaction with T-helper lymphocytes, become
activated and undergo somatic hypermutation and differentiation,
starting the auto-Ab production (2). Abs against neuronal surface Ag
may subsequently reach the central nervous system by crossing the
blood–brain barrier (BBB) at sites of increased permeability (3a). It is
also likely that activated B-lineage cells are able to cross the BBB actively
and undergo the same differentiation process within the central nervous
system, contributing to the intrathecal pool of auto-Abs (3b). When the
Abs reach their target, the normal function of the surface Ag (usually a
ionic channel; 4a) can be altered by different mechanisms. The Abs may
prevent the binding of the channel ligand (blocking; 4b); some Abs cause
cross-linking and internalization of receptors and thus depletion from the
cell surface (4c); finally, Abs may activate the complement cascade and
induce neuronal death (4d)
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NMDAR Abs are usually found in serum and CSF [6, 7,
10]. One study suggested serum testing alone was sufficient for
diagnosis, as NMDAR Abs were not detected in the CSF of a
few patients with NMDAR Ab encephalitis [6]. However, a
study of 250 individuals with NMDAR Ab encephalitis
showed that NMDAR Abs, detected using 2 different assays,
were present in the CSF of all patients tested, while they were
absent from the serum of about 8 % of these patients [10], and
the authors recommend testing CSF for diagnosis. The main
commercial assay for NMDARAbs uses this approach but it is
not clear whether the sensitivity is the same, and a multicenter
study of clinically defined patients needs to be performed.
Absolute titers of NMDAR Ab are higher in serum than
CSF [6], but if the IgG concentration in CSF is normalized to
that in serum, the relative NMDAR Ab concentration in CSF
is almost always higher [7], indicating specific intrathecal
production of NMDAR Abs [6, 7]. This is usually taken as
evidence of pathogenicity, and of the pathogenic relevance of
the CSFAbs, but, in fact, the relative contributions of systemic
and intrathecal NMDAR Abs to the disease pathology are
difficult to assess and have not been clearly established.
Notably, in some diseases [see voltage-gated potassium chan-
nel (VGKC)-complex/leucine-rich, glioma inactivated 1
(LGI1) Abs], intrathecal production is much less evident.
NMDAR Ab encephalitis has now been described in all
age groups, including infants and the elderly, but it remains
chiefly a disease of young women, who comprise 70–100 %
of case series [5–8, 11, 12], with a median age at presentation
of 21–23 years [6–8]. Initially, most cases were reported to be
associated with ovarian teratomas, or rarely other tumors [5,
7], but as case ascertainment has increased, the proportion of
tumor cases has dropped to 21–38 % [6, 8], largely because of
the increased recognition of NMDAR Ab encephalitis in chil-
dren and males, in whom tumors are much less common [8,
12]. Indeed, the largest cohort studied to date (577 patients)
indicated that 18–41-year-old women were most at risk, and
that children of both sexes aged<12 years, or males, rarely
had tumors [8]. In older adults, the prevalence of other tumors,
mostly carcinomas, increase again to around 23 % of patients
aged 45–84 years [13].
What is the Evidence for the NMDAR Abs Being
Pathogenic?
NMDAR are a subset of ionotropic glutamatergic receptors
mediating excitatory neurotransmission. They are ubiquitous
in the CNS and, additionally, play key roles in synaptic plas-




























Fig. 2 Live and fixed cell-based assay (CBA) for the detection of
neuronal surface antigen (Ag) Abs. The CBA is a technique that allows
identification of Abs whilst preserving the tertiary structure of the antigen.
Live human embryonic kidney (HEK) cells are transfected using
plasmids that contain DNA coding for the antigenic target (1);
transfected cells express the Ag mainly (but not exclusively) on their
surface (2); cells can either be stained live (a), or be fixed and
permeabilized (b), and are subsequently incubated with patient serum or
cerebrospinal fluid (3). Specific Abs in the serum or cerebrospinal fluid
will bind the expressed antigenic target; note that when cells are alive
specific Abs are able to bind only antigenic targets expressed on the cell
surface (a), whilst when cells are fixed/permeabilized intracellular Ags
can be reached (b). Cells are then incubated with a secondary fluorescent
Ab that recognizes human IgG (4) and the presence of fluorescent
antihuman IgG is detected with a fluorescent microscope (5)
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supported by clinical observations and some in vitro and
in vivo work. First, the early symptoms of NMDAR Ab
encephalitis—cognitive deficits, anterograde memory loss,
and psychiatric features—bear some resemblance to symp-
toms caused by NMDAR antagonists in both healthy humans
and animal models [14]. Second, CSF NMDARAb titers, and
to a lesser extent serum titers, correlate broadly with disease
course [10]. Indeed, a rapid fall in CSF titers was reported to
occur in patients with a monophasic illness and good out-
come, whereas the reduction was slower in those with poor
outcome [10]. Serum titers drop in successfully treated pa-
tients and remain elevated in those with poor outcome or death
[6]. Nevertheless, both serum and CSFAbs can be detected in
many patients after treatment and recovery [6, 10, 15]. This
has management implications with respect to whether and for
how long to continue immunotherapies, but in other diseases
such as myasthenia gravis, positive Ab titers after good recov-
ery are not uncommon.
NMDAR Abs in patient CSF cross-link surface NMDAR,
and thus trigger the internalization of the Ag–Ab complex, lead-
ing to selectively reduced NMDAR cluster density on dendrites
of cultured neurons and reduced NMDAR-mediated currents
[16]. Decreased NMDAR staining intensity in the hippocampi
of patientswithNMDARAb encephalitis has also been observed
at autopsy compared with non-NMDAR Ab encephalitis con-
trols. This suggests a specific effect of the Abs in reducing
NMDARs similar to those seen in vitro [16].
To provide definitive proof of pathogenicity, recapitulation
of disease features in experimental animals injected with the
Ab is required. In vivo evidence of pathogenic effects of
NMDAR Abs is still sparse, but a recent study demonstrated
memory deficits and some anhedonic behaviors in mice ex-
posed to NMDAR Abs by intracerebroventricular infusion
over 14 days, with recovery after cessation of infusion [17].
There was a concomitant reduction in hippocampal NMDAR
clusters. Although a limited phenotype was obtained (no sei-
zures, movement disorder, or reduction in consciousness), this
finding is still an important demonstration that the effects of
the patient Abs in vitro do translate to relevant behavioral
changes, and justifies the removal of Abs with immunomod-
ulatory treatments. Another study was able to demonstrate
increased seizure susceptibility in mice given a single bolus
of purified NMDAR Ab IgG with pentylenetetrazol (PTZ) as
a proconvulsant [18].
Treatment
Supportive evidence for pathogenicity is the response to immu-
nomodulatory treatments. There are no prospective trials of dif-
ferent immunomodulatory regimes or agents in NMDAR Ab
encephalitis but there are 4 medium-to-large retrospective obser-
vational cohorts [6–8, 19], and many small case series and case
reports (see Tables 1 and 2). These, mainly retrospective data,
can provide useful information on different treatment regimes, as
well as the justification for different approaches.
Tumor Resection
All teratomas examined histologically were found to contain
neurons that expressed NMDAR, and were able to bind patient
Abs. When present, resection of the tumor is important for
recovery [6–8] In most patients, a combination of surgery and
first-line immunotherapy [corticosteroids, intravenous immu-
noglobulin (IVIg) and plasma exchange (PLEX)] is required
[6, 9, 11, 21, 22], and results in improvement in up to 80 % of
patients [9]. This highlights the importance of performing a
thorough tumor search early in the course of any autoimmune
encephalitis, especially in females aged 12–45 years, and black
and Asian women, in whom teratomas are found in nearly half
the cases of NMDAR Ab encephalitis [8].
First-line Immunotherapy
Whereas tumor resection is important in those with an ovarian
teratoma, first-line immunotherapy alone (corticosteroids,
IVIg, PLEX alone or in combination) results in satisfactory
clinical improvement in approximately half the patients with
nonparaneoplastic NMDAR Ab encephalitis [8, 9, 12, 13].
Generally, the efficacy of individual first-line treatments can-
not be distinguished in these studies, as the clinicians chose
the treatments or combination of treatments, based on avail-
ability, perceived risk, and other factors, and there were no
comparison regimes. One case series of 9 patients found that,
in those patients who ultimately had a good outcome, PLEX
had been started early and had been part of the initial therapy
(alone or with corticosteroids) [23]. However, there was such
heterogeneity in the patients, both in terms of presence of
teratoma and timing and types of treatment, that disentangling
the effect of PLEX itself seems ambitious. There were few
adverse events associated with the use of PLEX. Perhaps a
more appropriate conclusion is that early immunomodulatory
treatment may be better than late treatment and that PLEX
appears safe in patients with NMDAR Ab encephalitis, in-
cluding those with autonomic dysfunction.
The case for early treatment has been made in several stud-
ies [6, 8, 12, 15, 24–26]: a small case series reported that 4 of 5
children treated with combinations of first-line immunothera-
py within 6 days of symptom onset recovered fully with no
relapses [24]. The strongest evidence in favor of early treat-
ment comes from the largest observational cohort published,
which demonstrated that early treatment, the lack of need for
intensive care admission, and maximum mRS score of≤ 3
were independently associated with good outcome [8]. In that
study, about half the patients who received first-line immuno-
therapy improved within 4 weeks of treatment, and 97 % of



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































152 Gastaldi et al.
these patients went on to have a good outcome (mRS 0–2) at
24 months of follow-up.
Most studies have used the modified mRS to measure out-
come. Even in those patients classified as having good out-
come (mRS 0–2), deficits in executive function and memory
are common and are more severe in those with delayed treat-
ment [15]. This would suggest that the initial part of the illness
may be critical in terms of neuronal damage and long-term
sequelae. Pathological studies have not demonstrated signifi-
cant complement deposition and cytotoxicity but have gener-
ally been conducted late in the disease and after some immu-
notherapy [27, 28]. Perhaps complement or cell-mediated tox-
icity might occur in the early stages of disease if left untreated,
setting the path for an incomplete recovery in such patients.
Second-line Immunotherapy
The most commonly used second-line immunotherapies are
rituximab and cyclophosphamide alone or in combination.
The use of other agents, such as methotrexate (MTX), azathi-
oprine (AZA), and mycophenolate mofetil (MMF), has not
been reported widely enough to permit conclusions to be
drawn about their effectiveness, and are more relevant to
long-term maintenance. Second-line immunotherapy is re-
quired more often in patients with nonparaneoplastic
NMDAR Ab encephalitis [8], and substantial improvements
are seen in around 75 % of patients treated [7–9, 11–13, 23,
25]. In the largest observational cohort [8], the use of second-
line immunotherapy was also identified as a predictive factor
for good outcome. Relapses are also less likely in those treated
with second-line immunotherapy [8, 29].
At present, it is not possible to determine which drug, com-
bination of drugs, or regime is most effective. The most com-
monly used regimes areweekly rituximab infusion for 4weeks
and monthly cyclophosphamide infusion for up to 6 months.
Few serious adverse effects have been observed in adults. By
contrast, a 7.6 % rate of infection (2.8 % causing disability or
death) and 2.0 % rate of anaphylactic infusion reactions were
reported in 1 study of children with NMDAR Ab encephalitis
and other inflammatory and autoimmune CNS disorders [30].
Anaphylactic reactions or infections were reported in 2 % of
patients with NDMARAb encephalitis treated with rituximab,
and infection or severe lymphopenia causing discontinuation
of treatment in 2.5 % of patients receiving cyclophosphamide
[8]. Progressive multifocal leukoencephalopathy has not been
reported in the NMDARAb encephalitis literature in the>130
patients treated with rituximab alone or in combination with
other immunomodulatory agents [3, 7, 8, 11, 12, 23].
Cyclophosphamide treatment did not lead to any irreversible
adverse effects in any of the cohorts included, but, in view of
the age distribution of NMDAR Ab encephalitis, it is impor-
tant to bear in mind the risk of gonadal failure and infertility,
as well as malignancy, in patients receiving large cumulative
doses of the drug [25].
Cyclophophamide, but not rituximab, is able to cross the
BBB, which is not overall disrupted in patients with NMDAR
Ab encephalitis [7]. While the effect of rituximab may be to
reduce the supply of B-cell precursors to CNS plasmablasts,
and alter the resultant inflammatory environment in the CNS
[31], cyclophosphamide could have a direct effect on intrathe-
cal Ab synthesis.
Few studies have systematically studied the effect of im-
munotherapy on Ab levels. CSF titers mirrored the clinical
course more closely than serum levels in a study of 10 patients
[10], but the effect of first- and second-line treatments were
not differentiated. Case reports occasionally describe reduc-
tion [6, 22, 26, 32] or eradication [33, 34] of NMDAR Abs in
serum following first-line immunotherapy in patients with
good outcome, with concomitant decrease in CSF titers [6,
22, 26, 32–34]. Reductions in CSF titers with second-line
treatments have also been demonstrated [31, 35, 36], but for
obvious practical reasons CSF titers are not widely available
in patients who have improved. Successful aggressive immu-
nosuppression with intrathecal MTX and intravenous (IV)
alemtuzumab was reported in 4 children [37, 38], 2 of whom
were refractory to prolonged immunotherapy, including cy-
clophosphamide and/or rituximab. In 2 cases, intrathecal ther-
apy with MTX was associated with a reduction in CSF Ab
levels, which was followed by a much slower and inconsistent
drop in serum levels [37]. Intrathecal MTX treatment carries
the risk of long-term cognitive impairment, which may con-
tribute to the sequelae of NMDAR Ab encephalitis, and
should therefore only be considered if lack of response to
more commonly used agents is well established.
One remarkable feature of NMDAR Ab encephalitis is the
prolonged recovery, with progressive improvements in cogni-
tive domains noted for months and even years following the
end of treatment [13, 32]. Although this may be related to the
recovery of physiological NMDAR homeostasis as the Ab
levels decline, the role of persistent NMDAR Abs in treated
patients is not yet clear. Prospective studies are needed to
demonstrate the relationship between CSF and serum titers,
stage of disease, treatment responses, and final outcomes, in-
cluding detailed cognitive and mental state.
Relapses
The relapse rate in NMDAR Ab encephalitis is reported to be
12–25 % [6–8, 11, 29], and relapses may occur months to
several years after the initial episode. They are often less se-
vere and may be mono- or pauci-symptomatic. In children,
atypical presentations such as cerebellar ataxia or brainstem
signs have been described [29]. Themajority of relapses occur
in patients who do not have a tumor associated with NMDAR
Ab encephalitis, those who received no or limited treatment
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for the initial episode [6–8, 11, 29], and those not exposed to
second-line agents [29]. Second-line immunotherapy also ap-
pears to prevent further relapses in those with a multirelapse
disease course [8]. At present, there is no clinical or
paraclinical predictive marker for relapses. Although alter-
ations in CSF Ab titers relate well to clinical changes [10], it
is impractical and perhaps unsafe to conduct CSF analysis for
predictive purposes in well patients. Changes in serum Ab
titers were not well correlated with relapses [10]. The effects
of long-term immunosuppression with oral agents such as
AZA or MMF on relapse rate is currently unknown.
NMDAR Ab Encephalitis Following Herpes Simplex
Virus Encephalitis
Some children and adults with herpes simplex virus (HSV)
encephalitis and subsequent relapses characterized by
choreoathetosis in children and behavioral/psychiatric fea-
tures in adults [39–41], were found to have NMDAR Abs
without HSV reactivation. They improved with immunother-
apy [39–42]. The absence of HSV DNA in the CSF at
the time of relapse could suggest that further antiviral
treatment is unnecessary, but in most cases reported,
aciclovir was given by default.
Voltage-gated Potassium Channel Complex
The voltage-gated potassium channel (VGKC) complex Abs
are the second most commonly identified Abs in CNS Ab-
mediated diseases, but the clinical spectrum and treatment
responses are very different from those of the NMDAR Ab
encephalitis. The clinical spectrum includes both central and
peripheral nervous system disorders.
There are many families and subtypes of VGKCs but the
Abs referred to here are those that immunoprecipitate Kv1.1,
1.2, and 1.6 subtypes from mammalian brain tissue extracts.
The VGKC complex is composed of Kv1 subunits and other
proteins that are tightly complexed with the Kv1 subunits in
the nerve membrane. They are widely expressed in the ner-
vous system, particularly at the juxtaparanodes of the nodes of
Ranvier, at peripheral motor nerve, and perhaps sensory ter-
minals, and in central synapses. Because opening of the
VGKC following each action potential leads to repolarization
of the membrane, VGKCs regulate neuronal activity through-
out the nervous system.
VGKC complex Abs were first described in association
with neuromytonia (NMT) or Isaac’s syndrome. This is char-
acterized by peripheral nerve excitability that manifests with
spontaneous muscle contraction, stiffness, sometimes im-
paired muscle relaxation [43], and a specific electromyogra-
phy pattern of burst of random discharges at high frequency in
the muscle fibers [44]. It is caused by hyperexcitability of the
motor nerves leading to repetitive and spontaneous activity in
the muscles. VGKC complex Abs were found in around 40 %
of patients with NMT and then more frequently and at higher
levels in patients with NMTassociated with dysautonomia and
CNS disturbance including insomnia and limbic dysfunction,
which is usually called Morvan’s syndrome (MoS) [45, 46],
and in a form of nonparaneoplastic limbic encephalitis (LE).
Although these Abs were initially identified by immuno-
precipitation of radioactive dendrotoxin-labeled VGKCs in
digitonin-solubilized mammalian brain homogenates, further
evidence indicated that they bind to protein components of the
VGKC complex rather than to the VGKC itself; their identi-
fication requires Ag-specific cell-based assays [47, 48]. The
main targets for the Abs are LGI1, typically associated with
LE, and a specific focal epilepsy, faciobrachial dystonic sei-
zures (FBDS), and contactin-associated protein like 2
(CASPR2), associated with a broader spectrum of central
and peripheral nervous system disorders such as LE, NMT,
or a combination of the two (MoS). A third antigen, contactin
2, has been identified, usually in patients with concomitant
anti-LGI1 or anti-CASPR2 Abs and with no specific pheno-
type, suggesting an unclear clinical relevance.
In some patients VGKC Abs are detected by radioimmu-
noassay, in the absence of LGI1, CASPR2, or contactin 2 Ab
specificity. In general, high titers (usually>400 pM) are more
frequently associated with defined clinical phenotypes (main-
ly LE, but also peripheral nerve hyperexcitability (PNH), sei-
zures, or MoS), whereas low titers of Abs can be found in
patients with either or both CNS and PNS syndromes but
are also detected in patients without a clear immune-
mediated phenotype [49–51]. It is possible that, in these cases,
the Abs bind to intracellular targets on the solubilized VGKC
complex [52].
VGKC Complex Ab LE
The most important association of VGKC complex Abs is
with LE. LE is defined as the combination of seizures, mem-
ory impairment, behavioral changes, and sleep disturbances,
and was previously thought to be only paraneoplastic with
Abs directed against intracellular cerebellar Ags [53]. LE with
Abs against the VGKC complex was the first form of CNS
disease shown to be potentially reversible and to respond re-
liably more quickly to immunotherapies [54]. Abs to LGI1 are
the most common finding and there is a good correlation be-
tween Ab titers and clinical syndrome, suggesting that they
are pathogenic [55]. Immunopathology studies of patients
with VGKC complex LE show, differently from NMDAR
Ab encephalitis, perivascular lymphocytic infiltration and
neuronal loss predominantly in the hippocampus and the
amygdala [56]. The presence of immunoglobulins and com-
plement deposition on neurons suggests that complement-
mediated neuronal death has—surprisingly, as a proportion
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of the Abs are IgG4, which does not activate complement—a
prominent role in the disease compared to T-cell-mediated
cytotoxicity [57]. There are few published in vitro or in vivo
data to support the pathogenicity of the CNS-directed Abs, but
purified IgG from a VGKC complex/LGI1 Ab serum
increased cell excitability in rat hippocampal slices within a
2-h incubation period [58], suggesting that the Abs have epi-
leptogenic properties. A more detailed and comprehensive
paper showed that the LGI1 Abs disrupted binding of LGI1
to its partners ADAM22 and ADAM23 in cultured neurons
with effects on the expression of α-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid receptors (AMPAR;
excitotoxic), suggesting that both presynaptic VGKCs and
AMPAR function might be reduced in these patients [59].
As AMPARs are excitatory and VGKCs have an inhibitory
effect on neuronal excitability the consequences of the
changes are difficult to predict.
Treatment of LE
A review of papers with relevant information regarding
VGKC complex Ab-associated disease management and out-
come is summarized in Supplementary Table 1. Most studies
are retrospective and there is a lack of standardizedmethods to
assess clinical status after treatment. Moreover, information
on treatment can be confused by the variability of the inclu-
sion criteria of studies that can be based either on clinical
presentation or on the target of the detected Ab.
Patients with VGKC-related disease can rarely improve
spontaneously or with anticonvulsant treatment alone [60],
but in the majority of cases immunosuppression is required
for sustained clinical improvement, especially in patients pre-
senting with LE [54, 61]. Marked improvement of cognitive
function and seizure control can occur shortly after adminis-
tration of immunotherapy, and the resolution of clinical symp-
toms often correlates well with Ab levels [62]. As previously
stated, the main Ag in LE is LGI1, but the disease can occur
also in association with CASPR2 Abs, also with a good re-
sponse to immunosuppression [63].
Different treatment options in the acute phase involve oral
or IV steroids, PLEX, and IVIg, but no randomized clinical
trial has established a first-line drug or optimal treatment du-
ration. Generally, 2 different approaches could be suggested:
1) starting with 1 first-line therapy (e.g., corticosteroids),
eventually switching to a combination therapy if incomplete
response or relapses manifest; or 2) starting with a combined
treatment (e.g., steroids plus IVIg). Published data suggest
that the latest approach could be preferable in terms of cogni-
tive improvement, and is also associated with a higher rate of
treatment-related complications [64]. Vincent et al. [62] re-
ported that although some patients presented a dramatic re-
sponse to PLEX or IVIg, most presented a consistent improve-
ment only after a few weeks of oral steroids. Thieben et al.
[61], after treating patients with VGKC Ab and LE with high
dose intravenous 6-methyl prednisolone (IVMP), found that
improvement was dramatic if patients were symptomatic
for ≤ 2 months. If clinical symptoms were present
for >9 months recovery was often incomplete, suggesting that
early treatment could be beneficial in LE.
In an open-label prospective trial, 9 of 9 patients with
VGKC complex Ab-related LE showed clinical improvement
after treatment with a combination of PLEX, IVIg, and IVMP
followed bymaintenance with oral steroids, further supporting
the notion that a combination therapy and prolonged immu-
nosuppression could be more effective in determining a long-
term remission [65].
Although compared with other Ab-mediated encephalopa-
thies, such as NMDAR Ab encephalitis, relapses are uncom-
mon in VGKC Ab-associated disease, recurrence of symp-
toms, sometimes as a result of suspension or noncompliance
of treatment, has been described. In these cases, symptom
recurrence is often associated with persisting serum Abs or
increasing titers [66]; these findings could therefore be helpful
in determining the opportunity of immunotherapy suspension.
In refractory cases, additional immunosuppression could
then be necessary. PLEX has shown improvement lasting for
several months in some patients either in combination or as
the only treatment, but is rarely considered as a long-term
option [67]. Different immunosuppressive drugs such as
AZA, MMF, tacrolimus, and rituximab have been used as
second-line or Bsteroid-sparing^ agents on a limited number
of patients, usually with more severe clinical presentation, and
the results are highly variable. Rituximab has been used in a
case series of 5 patients [68]. Despite the fact that all patients
were treated quite late in the history of the disease (at least
1 year after the first symptom), 2 of them showed a beneficial
effect, with reduction of seizures and cognitive improvement,
suggesting that the drug could be a valid option in refractory
patients. Even though the outcome of the disease is generally
good, many patients show residual memory deficits after the
resolution of the acute phase [69]. Whether a more aggressive
approach involving the use of an immunosuppressant like
rituximab in the early stages of the disease could prevent cog-
nitive impairment is intriguing, and needs to be explored.
Finally, the presence of a tumor is a rare event in patients
with VGKC Abs, especially if presenting as LE with LGI1
Ab, but can be more common in patients with MoS or NMT
with CASPR2 Abs. In such patients, a thymoma is common,
and the outcome is influenced by the evolution of the tumor
[46, 48].
FBDS
In around 20–40 % of patients with LGI1 Abs a specific sei-
zure type can precede the occurrence of full-blown LE [70].
These events have been described as Btonic seizures^ [71], or
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FBDS [66], and consist of brief and very frequent involuntary
movement with dystonic features involving mainly the arm,
the ipsilateral side of the face, and, less frequently, the leg. The
response to routinely used anticonvulsant drugs is usually
poor, but a dramatic reduction or complete resolution of the
FBDS can be obtained with oral steroids [72]. Irani et al. [66]
described a prospective cohort of 10 patients with FBDS,
where the development of cognitive impairment was only
present in patients who did not receive immunotherapy, sug-
gesting that early treatment can result in a better recovery and
sometimes prevent progression to encephalopathy.
Dipeptidyl-peptidase-like Protein-6
Dipeptidyl-peptidase-like protein-6 is a protein associated
with another VGKC, Kv4.2, that is responsible for regulating
firing rates of action potentials in dendrites in the central and
peripheral nervous system. Abs to dipeptidyl-peptidase-like
protein-6 were initially identified in patients with a form of
LE associated with gastrointestinal dysmotility (due to the
involvement of the myoenteric plexus), sleep disturbances,
cognitive and psychiatric manifestations, and dysautonomic
features [73], and subsequently in a disease presenting with
hyperekplexia, trunk rigidity, and cerebellar ataxia [74].
Overall, most patients seem to respond to immunosuppres-
sion, irrespective of the treatment strategy chosen. In a recent
review of 20 cases, 8 of 12 patients treated with immunother-




Abs to glutamic acid decarboxylase (GAD), the rate-limiting
enzyme in the synthesis of the inhibitory neurotransmitter γ-
aminobutyric acid (GABA), have been reported in a number
of different neurological syndromes, including stiff person
syndrome, cerebellar ataxia, LE, and epilepsy, as well as in
individual patients with isolated neurological symptoms. The
incidence of GAD Ab-associated LE is unknown as the liter-
ature consists mostly of case reports [76–82], and retrospec-
tive studies reporting 9 and 16 patients, respectively [83–85].
GAD Ab-associated encephalitis is often nonparaneoplastic
and presents as a more typical limbic syndrome than many
of the autoimmune encephalitides described above, with sub-
acute evolution of memory impairment and temporal lobe
seizures, which are mostly resistant to treatment with antiep-
ileptic drugs. Brain imaging usually reveals uni- or bilateral
medial temporal lobe hyperintensity on T2/fluid-attenuated
inversion recovery sequences. The role played by the GAD
Abs is unclear. GAD Abs are found in both serum and CSF of
patients with LE, and CSF-specific oligoclonal bands and in-
trathecal synthesis of GADAbs are most often present [76, 79,
84]. However, Ab access to its target is not straightforward as
GAD is an intracellular enzyme. Also, the range of syndromes
associated with GAD Abs would suggest that the Abs can
have different and nonoverlapping effects within the CNS. It
seems more likely that GAD Abs may be markers of the
immune-mediated process in LE: coexistence with GABAB
receptor (GABABR) Abs has been described [86], raising the
possibility that other cell surface Abs may be important, and
biopsies have demonstrated marked neuronal loss and T-cell
infiltrates, with no IgG deposition [57, 79, 84]. Of note, a
recent study [87] found GADAb-associated LE to be 10 times
more likely to be paraneoplastic than GADAb-associated stiff
person syndrome or cerebellar ataxia, but GAD Abs are quite
frequently found in patients with other, more pathogenic, Abs.
Indeed, older age and the presence of additional Abs against
neuronal cell-surface Ags (especially GABABR) were
markers of the paraneoplastic nature of the syndrome.
The effects of immunotherapy are variable and often dis-
appointing. Combinations of corticosteroids, IVIg, and PLEX
have been found to be effective in a number of case reports
[57, 77, 79, 82], but treatment often had to be continued for
several months [79, 82], or be augmented with a second-line
agent, most commonly MMF [76, 82]. Outcome measures
were generally not described and seizures often persisted
[82]. The two case series reported only very modest improve-
ments with immunotherapy [83, 84]. Seizure frequency re-
duced somewhat, although no patients became seizure-free
[84], and detailed neuropsychological assessment revealed
that although executive function improved, this was not
matched by an improvement in memory [83]. Ab levels ap-
peared to decrease with treatment but it is important to note
that in all cases they remained significantly elevated.
Overall, there is little doubt that an immune-mediated pro-
cess is taking place in the medial temporal lobes of patients
with LE and GAD Abs, and many patients reported thus far
were treated after significant delays. A potential beneficial
effect of early immunotherapy cannot be ruled out.
AMPAR
AMPAR are a subgroup of ionotropic glutamate receptor
mainly present in excitatory synapses of the CNS. Abs against
the extracellular domains of AMPA subunits GluR1 and
GluR2 were associated originally with a particularly aggres-
sive form of LE, often accompanied by the presence of a
tumor [88]. The largest case series reported describes 22 pa-
tients and shows that the clinical spectrum can include, in
addition to LE, psychosis and multifocal encephalopathy.
Administration of first-line treatment (steroids or IVIg) and,
when appropriate, tumor removal, often lead to a complete or
partial remission of the symptoms. The patients can relapse,
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but a more aggressive course of treatment involving rituximab
and/or cyclophosphamyde seems to be associated with a
monophasic disease [89].
GABABR
GABABR is a protein widely distributed in the brain and lo-
cated both pre- and postsynaptically. Genetic alterations of the
receptor are associated with epilepsy and cognitive impair-
ment, and Abs against the B1 subunit are found in patients
with LE and, rarely, ataxia, 50 % of whom will have a small-
cell lung carcinoma [86]. The administration of immunother-
apy, in association with chemotherapy or tumor removal, is
accompanied by a prompt improvement and, in a percentage
of cases, by a complete recovery [90]. Conversely, patients
that did not receive immunotherapy had a bad prognosis,
and death occurred in a high percentage of cases within
months from the onset of the neurological disease. Some pa-
tients have a poor outcome despite sustained immunosuppres-
sion, but that is often related to tumor progression or associ-
ated with the presence of Abs directed against intracellular
Ags such as GADAbs or amphyphysin Abs, which can reflect
the involvement of an additional cytotoxic T-cell mechanism
in the progression of the disease [91].
More recently, a novel Ab against GABAA receptor has
been described [92]. Pedrol-Petit et al. [92] reported 18 pa-
tients with Abs directed against the α1/β3 subunit of the re-
ceptor, 6 with high titers in serum and CSF and a definite
clinical picture, and 12 with low titers only on serum and
variable syndromes, often in association with other Abs.
Among the 6 patients with CSF Abs, only 1 had substantial
recovery with antiepileptic drugs alone, which had to be main-
tained for a long time to avoid recurrence. The remaining 5
patients received different immunotherapy regimens (either
steroids alone or in combination with IVIg, PLEX, cyclophos-
phamide or rituximab), with a consistent recovery in 3 of
them, whilst 2 died because of septic complications.
Another paper described 40 patients with Abs of the IgG
and IgM subclasses targeting the α1 and γ2 subunits of the
GABAA receptor [93]. Immunosuppressive treatment was ad-
ministered prospectively only to 1 patient, whose catatonia
and frontal dysfunction improved with a fall in Ab titres.
Glycine Receptor
Abs directed against the α1 subunit of the glycine receptor
(GlyR) have been described in patients with variants of stiff
person syndrome usually identified as progressive encephalo-
myelitis, rigidity, and myoclonus, which is characterized by
the association of rigidity, stimulus-sensitive spasms, myoclo-
nus, hyperkeplexia, autonomic disturbances, and brainstem
disorders [94]. In the only prospective case series, patients
treated with immunotherapy showed consistent improvement,
sometimes with complete resolution of clinical symptoms.
Therapeutic approaches were variable but typically involved
a combination of IVMP, PLEX, and IVIg followed by oral
prednisolone. Nevertheless, 6/45 patients relapsed and re-
quired prolonged immunosuppression with MMF, AZA, or
cyclophosphamide, which, at the time of publication, were
effective in preventing further relapses. Recently, GlyR Abs
have also been identified in association with isolated optic
neuritis [95], and they represented the most frequent Ab rec-
ognized in patients with focal adult epilepsy of unknown
cause [96]. However, in these studies the Abs were also found
in a consistent number of patients in the control group, the
titers did not correlate clearly with disease presentation or drug
administration, and the response to immunosuppression was
highly variable. The role of GlyR Abs in such conditions may
not be clinically helpful, although it could reflect the presence
of autoimmune mechanisms.
IgLON5
In 2014, a novel syndrome with sleep disorders (parasomnia
and breathing dysfunction), gait instability, and brainstem
symptoms was described in 8 patients in association with sur-
face Abs to the neuronal cell adhesion protein IgLON5 [97].
Neuropathological investigations in 2 patients identified tau
aggregates in the tegmentum of the brainstem and in the hy-
pothalamus that could not be classified within any known
tauopathy, suggesting a possible neurodegenerative etiology
of the disease. Moreover, despite immunosuppressive treat-
ments including steroids, IVIg, cyclophosphamide, and ritux-
imab, only 1 patient showed some improvement. Whether the
Abs are a primary or secondary element in the disease devel-
opment needs to be clarified.
Dopamine 2
Dale et al. [98], investigating the role of surface Abs in
suspected autoimmune movement disorders, identified Abs
to the extracellular domain of the dopamine receptor 2 in 12/
17 patients with basal ganglia encephalitis compared with
0/67 controls [98]. In addition, dopamine receptor 2 Abs were
found in a small number of patients with Tourette’s syndrome
and Syndenham’s chorea. Most patients in the study were
identified retrospectively and were given no immunotherapy,
presenting at the end of follow-up with persistent neurological
deficits. Interestingly, patients identified after the study who
received immunosuppression showed marked clinical im-
provement and a reduction in Ab titers (Dale et al., personal
communication), suggesting a consistent role of the Ab in
disease progression. Further studies are required to confirm
these data and help define an optimal treatment course.
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Metabotropic Glutamate Receptor
Subacute cerebellar ataxia associated with metabotropic glu-
tamate receptor type 1 Abs (mGluR1) is a rare clinical entity,
so far described in 3 reported patients [99, 100].
Paraneoplastic cerebellar degeneration is often associatedwith
Abs directed against cytoplasmic or nuclear Ags that are im-
portant for the diagnosis but unlikely to be directly responsible
for neuronal damage. By contrast, mGluR1Abs are directed at
a surface Ag on perisynaptic dendritic spines of Purkinje cells
and, in one study, shown to be pathogenic [99].
More recently, Abs directed to the mGluR5 Abs were iden-
tified in 2 patients with limbic encephalopathy and Hodgkin
lymphoma, a combination known as Ophelia syndrome [101].
In both cases prompt tumor treatment (excision or chemother-
apy) was performed, and 1 patient also received steroids,
resulting in complete regression of the symptoms.
Conclusions and Questions for the Future
Despite the interest in identifying the autoimmune forms of
encephalitis described here, and the introduction of auto-Ab
testing in centeRs around the world, the low prevalence of
these disorders and their relatively recent discovery has limit-
ed comparison of different treatment protocols. Prospective
studies on outcomes in patients with defined clinical and Ab
subtypes are required in the future, to define optimal therapeu-
tic strategies.
Despite these limitations, some general suggestions can be
made. First, many patients have improved considerably and
returned to a near-normal life. Although in these conditions
there is still much to know (possibility of wider clinical phe-
notypes, natural history, and long-term outcome, efficacy of
different immunotherapies), the relative safety of immune ac-
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Fig. 3 Management of voltage-gated potassium channel (VGKC)
complex-associated disease. The algorithm describes a management
approach to patients with central nervous system (CNS) syndromes and
the presence in serum or cerebrospinal fluid of Abs directed against the
VGKC complex, and it is intended as a general indication. Single patients
could need a tailored approach based on the clinical phenotype *Mainly
leucine-rich glioma inactivated 1 and contactin-associated protein like 2
(CASPR2) **The efficacy of different immunosuppressants has never
been tested systematically in autoimmune encephalitis, and previous
evidence suggests, for example, a better efficacy of mycophenolate
mofetil (MMF) than cyclophosphamide in other autoimmune diseases
[102]. Hence, the division between Bescalating^ and Bsteroid-sparing^
drugs is not clear-cut and different strategies could be applied in
different clinical settings MRI = magnetic resonance imaging; AED =
antiepileptic drugs; IVIg = intravenous immunoglobulin; PLEX =
plasma exchange; ACER = Addenbrooke’s Cognitive Examination
Revised; MMSE = Mini-mental State Examination; AZA = azathioprine
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treatment. Even when the clinical picture is not life-threaten-
ing, immunosuppression can be considered in the syndromes
associated with the NMDAR or VGKCAbs, and disease evo-
lution will be the main element guiding further decisions (e.g.,
treatment escalation or tapering). Although Ab titers in isola-
tion are not sufficient to guide treatment choice, carefully an-
alyzed serial samples can be helpful in deciding whether treat-
ments have been sufficient and in determining when to start
tapering the drugs.
Somewhat different approaches to treatment are required
for the different diseases. NMDAR Ab encephalitis is charac-
terized by long-lasting Abs in patients and often a prolonged
disease that can relapse. Moreover, some key feature of the
disease (such as hypoventilation) can be fatal. Thus, a rela-
tively aggressive treatment approach, with extensive use of
immunosuppressive drugs such as rituximab and cyclophos-
phamide for several months, may be justified, even in combi-
nation. However, the LGI1-associated disease spectrum spans
from patients with FBDS only to patients with severe enceph-
alopathies, and less persistent aggressive treatment is often
appropriate; PLEX or IVIg with oral steroids is successful in
many patients, although some require second-line therapies.
Relapses are not common, and steroid tapering can usually be
attempted within a year. An algorithm suggesting a general
approach in patients with VGKC associated disease is present-
ed in Fig. 3.
In contrast to NMDAR Abs, which are mainly IgG1, LGI1
Abs are mainly IgG4, a subclass that accounts for<5 % of
total IgG and is traditionally produced as an anti-inflammatory
mechanism after prolonged exposure to Ags [103]. However,
IgG4 Abs are now associated with several diseases involving
the nervous system (e.g., myasthenia with muscle-specific ki-
nase Abs) and other organs (pemphigus, Goodpasture’s syn-
drome, membranous nephropathy, thrombotic thrombocyto-
penic purpura) [104]. As these Abs are not able to activate
complement, the likely pathogenic mechanism is Ab binding
to essential functional sites on the Ag [105]. Interestingly, in
IgG4-related disease plasma cells that produce IgG4 are usu-
ally short lived [106], and rituximab has been shown to be
very effective in muscle-specific kinase Ab myasthenia.
Further studies will need to investigate whether the IgG sub-
type involved in the disease could have an impact on the
treatment strategy.
Finally, future studies will need to focus on increasing the
knowledge on pathophysiology of different Ab-mediated en-
cephalitides, leading to more pharmacological approaches to
use while immunotherapies take effect, and to develop more
targeted therapeutic strategies. For instance, new therapeutic
options should try to tackle intrathecal synthesis of specific
Abs in the CNS.
Rituximab is effective in depleting CD20+ cells, but in
patients treated intravenously CSF concentration of the drug
is only 0.2 % compared with serum [107, 108]. Therefore,
intrathecal drug administration could be more effective in re-
ducing CNS NMDAR Ab production. Natalizumab, a mono-
clonal Ab against α-4 integrin that affects trafficking of T and
B cells across the BBB [109], has been successful in multiple
sclerosis in altering the oligoclonal band pattern and the intra-
thecal synthesis. This drug could prevent B-cell trafficking
into the brain in NMDAR Ab encephalitis.
None of these drugs are without potential side effects but
the severity of the disease in some patients justifies further
consideration of these approaches.
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